CYDY – Today’s October 26 Announcement: More Reasons for Encouragement
I find today’s announcement particularly encouraging, and here’s why.
We’ve now seen CytoDyn report statistically significant ctDNA differences compared with historical standard-of-care patients at BOTH four weeks (p=0.0005) and eight weeks (p=0.0006). That’s important because we’re no longer looking at just one early molecular measurement. We’re seeing encouraging signals at multiple assessment points.
Consider what we know:
1. An 86% median ctDNA reduction at week two among 28 evaluable patients.
2. A 93.22% median ctDNA reduction at week four in the previously reported Natera comparison cohort.
3. Statistically significant molecular-response differences versus historical standard-of-care cohorts at both four and eight weeks.
4. No leronlimab-related adverse events above Grade 2, treatment discontinuations, or dose-limiting toxicities among the 32 patients with available safety data.
5. CCR5 expression confirmed in all 91 evaluable archival tumor samples, supporting the biological rationale for targeting this receptor.
What encourages me most is the developing consistency of the molecular evidence. We’re seeing substantial early reductions, favorable comparisons with historical treatment cohorts, and encouraging preliminary tolerability.
Now, does this establish improved overall survival or guarantee FDA approval? Of course not. We still need confirmed objective responses, durability, progression-free survival, and overall survival. And historical comparisons have limitations.
But there’s a substantial difference between acknowledging that additional evidence is needed and dismissing these findings as insignificant.
Clinical development is about building evidence, and today’s announcement adds another encouraging piece to that process.
I also find it interesting that the molecular findings are being reported at multiple time points rather than relying on a single favorable observation. While that doesn’t establish a durable clinical benefit, it certainly strengthens the case for continued investigation.
For those who have already declared CLOVER a dead end, I believe that conclusion is premature.
The data are not yet definitive, but neither are they inconsequential.
My takeaway: The scientific rationale for leronlimab continues to develop, and the next clinical milestones could be especially important.
I’m encouraged by the progress, realistic about what remains to be demonstrated, and looking forward to seeing how these molecular findings translate into actual patient outcomes.
One thing is certain: I’d much rather see encouraging clinical evidence that requires further validation than have no meaningful signal to investigate at all.
Go CYDY!
Source: CytoDyn, October 26, 2026
https://www.cytodyn.com/newsroom/press-releas...metastatic
I find today’s announcement particularly encouraging, and here’s why.
We’ve now seen CytoDyn report statistically significant ctDNA differences compared with historical standard-of-care patients at BOTH four weeks (p=0.0005) and eight weeks (p=0.0006). That’s important because we’re no longer looking at just one early molecular measurement. We’re seeing encouraging signals at multiple assessment points.
Consider what we know:
1. An 86% median ctDNA reduction at week two among 28 evaluable patients.
2. A 93.22% median ctDNA reduction at week four in the previously reported Natera comparison cohort.
3. Statistically significant molecular-response differences versus historical standard-of-care cohorts at both four and eight weeks.
4. No leronlimab-related adverse events above Grade 2, treatment discontinuations, or dose-limiting toxicities among the 32 patients with available safety data.
5. CCR5 expression confirmed in all 91 evaluable archival tumor samples, supporting the biological rationale for targeting this receptor.
What encourages me most is the developing consistency of the molecular evidence. We’re seeing substantial early reductions, favorable comparisons with historical treatment cohorts, and encouraging preliminary tolerability.
Now, does this establish improved overall survival or guarantee FDA approval? Of course not. We still need confirmed objective responses, durability, progression-free survival, and overall survival. And historical comparisons have limitations.
But there’s a substantial difference between acknowledging that additional evidence is needed and dismissing these findings as insignificant.
Clinical development is about building evidence, and today’s announcement adds another encouraging piece to that process.
I also find it interesting that the molecular findings are being reported at multiple time points rather than relying on a single favorable observation. While that doesn’t establish a durable clinical benefit, it certainly strengthens the case for continued investigation.
For those who have already declared CLOVER a dead end, I believe that conclusion is premature.
The data are not yet definitive, but neither are they inconsequential.
My takeaway: The scientific rationale for leronlimab continues to develop, and the next clinical milestones could be especially important.
I’m encouraged by the progress, realistic about what remains to be demonstrated, and looking forward to seeing how these molecular findings translate into actual patient outcomes.
One thing is certain: I’d much rather see encouraging clinical evidence that requires further validation than have no meaningful signal to investigate at all.
Go CYDY!
Source: CytoDyn, October 26, 2026
https://www.cytodyn.com/newsroom/press-releas...metastatic
10
CytoDyn Inc (CYDY) Stock Research Links
LETS GO!!!
